China's GLP-1 Weight-Loss Market Faces Rising Price Competition -- Market Talk

Dow Jones12-16

1000 GMT - Pricing competition in China's GLP-1 weight-loss drug market is expected to heat up, HSBC analysts say in a note. The inclusion of Eli Lilly's tirzepatide treatment in China's national reimbursement drug list was a surprise to the market and raises concerns about the sales outlook of Innovent's mazdutide drug, they say. A price cut for GLP-1 drugs will quickly raise market penetration as the treatments only received approval in China in 2025. However, given there are multiple domestic GLP-1 treatments in the pipeline, a more aggressive pricing strategy may hurt sales for all drugmakers, they add. HSBC awaits more updates from China's oral GLP-1 developers, including Ascletis and Hengrui. The bank maintains a buy call on Innovent and hold ratings on Livzon and Fosun Pharma. (jason.chau@wsj.com)

(END) Dow Jones Newswires

December 16, 2025 05:00 ET (10:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591898820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591898820","market":"nz","top_or_hot":-1,"title":"China's GLP-1 Weight-Loss Market Faces Rising Price Competition -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1000 GMT - Pricing competition in China's GLP-1 weight-loss drug market is expected to heat up, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts say in a note. The inclusion of Eli Lilly's tirzepatide treatment in China's national reimbursement drug list was a surprise to the market and raises concerns about the sales outlook of Innovent's mazdutide drug, they say. A price cut for GLP-1 drugs will quickly raise market penetration as the treatments only received approval in China in 2025. However, given there are multiple domestic GLP-1 treatments in the pipeline, a more aggressive pricing strategy may hurt sales for all drugmakers, they add. HSBC awaits more updates from China's oral GLP-1 developers, including Ascletis and Hengrui. The bank maintains a buy call on Innovent and hold ratings on Livzon and Fosun Pharma. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 05:00 ET (10:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's GLP-1 Weight-Loss Market Faces Rising Price Competition -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's GLP-1 Weight-Loss Market Faces Rising Price Competition -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-16 18:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1000 GMT - Pricing competition in China's GLP-1 weight-loss drug market is expected to heat up, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts say in a note. The inclusion of Eli Lilly's tirzepatide treatment in China's national reimbursement drug list was a surprise to the market and raises concerns about the sales outlook of Innovent's mazdutide drug, they say. A price cut for GLP-1 drugs will quickly raise market penetration as the treatments only received approval in China in 2025. However, given there are multiple domestic GLP-1 treatments in the pipeline, a more aggressive pricing strategy may hurt sales for all drugmakers, they add. HSBC awaits more updates from China's oral GLP-1 developers, including Ascletis and Hengrui. The bank maintains a buy call on Innovent and hold ratings on Livzon and Fosun Pharma. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 05:00 ET (10:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591898820","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591898820","pubTimestamp":1765879200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1000 GMT - Pricing competition in China's GLP-1 weight-loss drug market is expected to heat up, HSBC analysts say in a note. The inclusion of Eli Lilly's tirzepatide treatment in China's national reimbursement drug list was a surprise to the market and raises concerns about the sales outlook of Innovent's mazdutide drug, they say. A price cut for GLP-1 drugs will quickly raise market penetration as the treatments only received approval in China in 2025. However, given there are multiple domestic GLP-1 treatments in the pipeline, a more aggressive pricing strategy may hurt sales for all drugmakers, they add. HSBC awaits more updates from China's oral GLP-1 developers, including Ascletis and Hengrui. The bank maintains a buy call on Innovent and hold ratings on Livzon and Fosun Pharma. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4590":"PTP","GLP":"Global Partners Lp","BK4585":"ETF&股票定投概念","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","HSBC":"汇丰","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4521":"英国银行股","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK4207":"综合性银行","BK4144":"石油与天然气的储存和运输"},"translate_title":"中国GLP-1减肥市场面临价格竞争加剧--市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSBC":0.7,"GLP":1.5},"content_text":"1000 GMT - Pricing competition in China's GLP-1 weight-loss drug market is expected to heat up, HSBC analysts say in a note. The inclusion of Eli Lilly's tirzepatide treatment in China's national reimbursement drug list was a surprise to the market and raises concerns about the sales outlook of Innovent's mazdutide drug, they say. A price cut for GLP-1 drugs will quickly raise market penetration as the treatments only received approval in China in 2025. However, given there are multiple domestic GLP-1 treatments in the pipeline, a more aggressive pricing strategy may hurt sales for all drugmakers, they add. HSBC awaits more updates from China's oral GLP-1 developers, including Ascletis and Hengrui. The bank maintains a buy call on Innovent and hold ratings on Livzon and Fosun Pharma. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 05:00 ET (10:00 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591898820","isCrawlerRequest":true}